Compare Salesforce Inc (CRM) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Salesforce Inc vs GeneDx Holdings Corp — how do they compare? Salesforce Inc trades at $227.87 (market cap $187.48B), while GeneDx Holdings Corp trades at $67.41 (market cap $2.02B). The key difference: Salesforce Inc is far larger — about 92.8× GeneDx Holdings Corp's market cap, and Salesforce Inc pays a 0.77% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Salesforce Inc for 89 Days and GeneDx Holdings Corp for 19 Days on average.
| CRM | WGS | |
|---|---|---|
Market Cap | $187.48B | $2.02B |
Volume | 6,155,822 | 734,640 |
Sector | Technology | Health |
52-Week High | $266.23 | $167.51 |
52-Week Low | $150.12 | $34.51 |
Typical Hold Time | 89 Days | 19 Days |
Enterprise Value | $217.82B | $2.05B |
Dividend Yield | 0.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Salesforce (CRM) trades at $228.19, up 1.61% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows bearish technical signals but maintains robust fundamentals with 77.3% gross margins and 22% net income margin. Recent news highlights AI-driven growth potential despite sector-wide software stock volatility. Analyst consensus remains strongly bullish with a $271.91 price target, representing 19% upside potential from current levels.
CRM presents a compelling opportunity with strong profitability and AI monetization driving growth, though technical weakness and sector headwinds pose near-term risks. The company's rule of 44 performance and expanding free cash flow support long-term upside, but investors should monitor competitive pressures and macroeconomic conditions affecting software valuations.
GeneDx (WGS) trades at $68.50, down 0.04% with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue of $114.4M beating expectations but net income margin remains negative at -23.4%. Recent developments include new product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus targets $81.00 (18% upside), fundamental challenges persist with negative profitability metrics and high valuation multiples. The stock faces execution risks amid competitive genomics landscape, but operational improvements and testing volume growth provide potential catalysts for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
